Form 4: Centessa CTQO Exercises Options, Sells Shares

Centessa Pharmaceuticals' Chief Technology & Quality Officer, Tia L. Bush, exercised stock options and subsequently sold an equal number of shares under a pre-arranged trading plan.

Summary

• Tia L. Bush, Chief Technology & Quality Officer of Centessa Pharmaceuticals plc, engaged in transactions on November 17, 2025.
• Exercised 40,000 share options at an exercise price of $9.42 per share.
• Immediately sold 40,000 Ordinary Shares at a price of $28.00 per share.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on September 14, 2024.
• Following these transactions, beneficial ownership of Ordinary Shares decreased from 161,503 to 121,503.
• Remaining derivative securities (share options) total 360,338.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. While an officer sold shares, it was a pre-planned transaction under a 10b5-1 plan, which mitigates concerns about opportunistic selling. The officer also realized a substantial gain, which is a positive for the individual.

Positives

• The officer realized a significant gain by exercising options at $9.42 and selling at $28.00, indicating a profitable transaction for the individual.
• The transaction was pre-planned under a Rule 10b5-1 plan, suggesting it was not based on new, undisclosed material information.

Negatives

• A reduction in direct beneficial ownership by a key officer could be perceived negatively by some investors, although it was a pre-planned sale.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May view the sale as a slight negative due to reduced insider ownership, but the 10b5-1 plan mitigates concerns. The profitable exercise and sale could be seen as a positive sign of value realization.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The Form 4 filing details a pre-planned transaction by a Chief Technology & Quality Officer, involving the exercise of options and subsequent sale of shares. This type of transaction, executed under a Rule 10b5-1 plan, is generally considered routine and does not typically signal new material information about the company's prospects. While the officer reduced their direct share ownership, the transaction was profitable for the individual, reflecting a gain from the option exercise. Without additional context from other company filings or market data, this specific Form 4 alone does not provide sufficient grounds for a 'buy' or 'sell' recommendation, thus a 'hold' stance is appropriate.

Keywords

Centessa Pharmaceuticals, CNTA, Form 4, Insider Trading, Stock Options, Share Sale, Rule 10b5-1, Tia L Bush, Officer Transaction